Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features

Journal of Dermatology

Volumn 41, Issue 1, 2014, Pages 76-83

  An, Xiangjie ^a   Xu, Guangfen ^b   Yang, Liu ^a   Wang, Yuejue ^a   Li, Yan ^a   McHepange, Uwesu O ^a   Shen, Guanxin ^c   Tu, Yating ^a   Tao, Juan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

cutaneous squamous cell carcinoma; hypoxia inducible factor 1 ; prolyl hydroxylases 2; vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE DOMAIN PROTEIN 2; UNCLASSIFIED DRUG; VASCULOTROPIN; EGLN1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; BOWEN DISEASE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OLIGONUCLEOTIDE PROBE; PRECANCER; SAMPLE SIZE; SEBORRHEIC KERATOSIS; SKIN CARCINOMA; TUMOR GROWTH; ANOXIA; BOWEN'S DISEASE; COMPLICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS;

ANOXIA; BOWEN'S DISEASE; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; KERATOSIS, SEBORRHEIC; MALE; MIDDLE AGED; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892832222     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12314     Document Type: Article

References (37)

1. Jokilehto T, Rantanen K, Luukkaa M, et al,. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res 2006; 12: 1080-1087.
2. Brown JM, Wilson WR,. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-447.
3. Henze AT, Riedel J, Diem T, et al,. Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res 2010; 70: 357-366.
4. Boddy JL, Fox SB, Han C, et al,. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005; 11: 7658-7663.
5. Acker T, Acker H,. Cellular oxygen sensing need in CNS function: physiological and pathological implications. J Exp Biol 2004; 207: 3171-3188.
6. Talks KL, Turley H, Gatter KC, et al,. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-421.
7. Zhong H, Agani F, Baccala AA, et al,. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res 1998; 58: 5280-5284.
8. Zhong H, De Marzo AM, Laughner E, et al,. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
9. Poon E, Harris AL, Ashcroft M,. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 2009; 11: e26.
10. Harris AL,. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
11. Hicklin DJ, Ellis LM,. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
12. Shen J, Samul R, Silva RL, et al,. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225-234.
13. Murata M, Takanami T, Shimizu S, et al,. Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). Curr Eye Res 2006; 31: 171-180.
14. Gordan JD, Simon MC,. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007; 17: 71-77.
15. Ricker JL, Chen Z, Yang XP, et al,. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 2004; 10: 8665-8673.
16. Appelhoff RJ, Tian YM, Raval RR, et al,. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279: 38458-38465.
17. Berra E, Benizri E, Ginouves A, et al,. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22: 4082-4090.
18. Maxwell PH, Wiesener MS, Chang GW, et al,. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
19. Meijer TW, Kaanders JH, Span PN, et al,. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 2012; 18: 5585-5594.
20. Chaux A, Albadine R, Toubaji A, et al,. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 2011; 35: 1014-1020.
21. Han CP, Kok LF, Wang PH, et al,. Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol 2009; 22: 797-806.
22. Eckert AW, Kappler M, Schubert J, et al,. Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients. Oral Maxillofac Surg 2012; 16: 189-196.
23. Eckert AW, Lautner MH, Schutze A, et al,. Coexpression of hypoxia-inducible factor-1alpha and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology 2011; 58: 1136-1147.
24. Semenza GL,. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
25. Tao J, Tu YT, Huang CZ, et al,. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br J Dermatol 2005; 153: 715-724.
26. Koshikawa N, Iyozumi A, Gassmann M, et al,. Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 2003; 22: 6717-6724.
27. Semenza GL,. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000; 19: 59-65.
28. Chan DA, Giaccia AJ,. PHD2 in tumour angiogenesis. Br J Cancer 2010; 103: 1-5.
29. Soilleux EJ, Turley H, Tian YM, et al,. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology 2005; 47: 602-610.
30. Epstein AC, Gleadle JM, McNeill LA, et al,. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43-54.
31. McMahon S, Charbonneau M, Grandmont S, et al,. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 2006; 281: 24171-24181.
32. Hewitson KS, Lienard BM, McDonough MA, et al,. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 2007; 282: 3293-3301.
33. Barth S, Nesper J, Hasgall PA, et al,. The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol 2007; 27: 3758-3768.
34. Shen G, Li X, Jia YF, et al,. Hypoxia-regulated microRNAs in human cancer. Acta Pharmacol Sin 2013; 34: 336-341.
35. Nguyen MP, Lee S, Lee YM,. Epigenetic regulation of hypoxia inducible factor in diseases and therapeutics. Arch Pharm Res 2013; 36: 252-263.
36. Chan DA, Kawahara TL, Sutphin PD, et al,. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009; 15: 527-538.
37. Lee KA, Lynd JD, O'Reilly S, et al,. The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. Mol Cancer Res 2008; 6: 829-842.